FDAnews Drug Daily Bulletin

VIOQUEST PHARMACEUTICAL'S TARGETED CANCER THERAPEUTIC FOR SOLID TUMORS BEGINS TRIALS AT MOFFITT CANCER CENTER

May 31, 2006
A A

VioQuest Pharmaceuticals, a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P).
PR Leap